
==== Front
Oncol Rep
Oncol Rep
Oncology Reports
1021-335X
1791-2431
D.A. Spandidos

39219268
10.3892/or.2024.8805
OR-52-5-08805
Review
Routes and molecular mechanisms of central nervous system involvement in acute myeloid leukemia (Review)
Chen Liucui 1*
Zeng Piaorong 2*
Tang Huifang 3456
Chen Gang 7
Xie Juan 1
Yang Xiaoyan 1
Lei Xiaoyong 18
1 School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China
2 Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China
3 Hunan Provincial Key Laboratory of Multi-omics and Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, P.R. China
4 The First Affiliated Hospital, Department of Cardiology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China
5 Clinical Research Center for Myocardial Injury in Hunan, Hengyang, Hunan 421001; P.R. China
6 The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China
7 Department of Neurology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China
8 Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, Hunan 421001, P.R. China
Correspondence to: Professor Xiaoyong Lei, School of Pharmaceutical Science, Hengyang Medical School, University of South China, 28 Changshengxi Road, Hengyang, Hunan 421001, P.R. China, E-mail: leix_yong@163.com
* Contributed equally

11 2024
28 8 2024
28 8 2024
52 5 14601 6 2024
08 8 2024
Copyright: © 2024 Chen et al.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Acute myeloid leukemia (AML) is a predominant form of leukemia. Central nervous system (CNS) involvement complicates its diagnosis due to limited diagnostic tools, as well as its treatment due to inadequate therapeutic methodologies and poor prognosis. Furthermore, its incidence rate is unclear. The mechanisms of AML cell mobilization from the bone marrow (BM) to the CNS are not fully elucidated, and the molecular factors contributing to CNS infiltration are insufficiently recognized. The present review aimed to enhance the understanding of CNS involvement of AML and its impact on CNS. The latest research on the pathways and mechanisms facilitating AML cells to escape the BM and infiltrate the CNS was reviewed. Additionally, novel therapeutic strategies targeting specific molecules and genes for treating CNS involvement in AML were examined.

AML
CNS
cell adhesion molecules
brain barrier
therapeutic strategies
Innovation Platform and Talent Program2023TP1047 Natural Science Foundation of Hunan2023JJ30547 Major Project of Hunan Provincial Health CommissionW20241008 Clinical Research 4310 Program of the First Affiliated Hospital of the University of South China20214310NHYCG03 The present study was supported by the Innovation Platform and Talent Program (grant no. 2023TP1047), the Natural Science Foundation of Hunan (grant no. 2023JJ30547), the Major Project of Hunan Provincial Health Commission (grant no. W20241008) and the Clinical Research 4310 Program of the First Affiliated Hospital of the University of South China (grant no. 20214310NHYCG03).
==== Body
pmc1. Introduction

Acute myeloid leukemia (AML), a prevalent form of leukemia, poses significant treatment challenges and is frequently associated with specific chromosomal abnormalities. Symptoms predominantly include fever, bone pain and bleeding (1,2). Despite advancements in personalized therapy (3) improving diagnosis and treatment (4–6), central nervous system (CNS) involvement remains a significant contributor to severe complications and mortality in patients with AML, hindering effective long-term disease management (7–9). Although CNS infiltration and tumor formation are rare in adult patients with AML (10,11), they occur more commonly in pediatric patients (12). In adults, CNS involvement incidence ranges from 0.6–3% (13), with a recurrence rate of ~2.9–4.1% (10,13,14).

However, the rate of CNS infiltration by AML cells in adults may be significantly underestimated due to detection challenges (7,10). Previous studies indicated that up to 32% of cerebrospinal fluid (CSF) samples and 46% of autopsy specimens from adult patients with AML reveal CNS involvement (15,16). Paul and Short (17) reported a CNS involvement rate of 3.2%, with 52% of patients with AML who underwent CSF screening testing positive for leukemia cells. In a recent study, flow cytometry detected AML cells in the CSF of 645 patients with AML, showing 41.7% positivity among those without neurological symptoms (18). This substantial disparity arises primarily because lumbar puncture (LP) assessments are typically performed only on patients with neurological symptoms (19). Although clinical symptoms and neuroimaging can indicate CNS involvement, their sensitivity and specificity vary, with LP remaining the diagnostic gold standard (20).

In patients with AML, 58% exhibit clinical symptoms such as headaches, vomiting, fatigue, cognitive changes, seizures and various cranial nerve palsies, which are often subtle and difficult to differentiate from drug side effects (21–23). Although CNS radiological imaging techniques, including magnetic resonance imaging and computer tomography, demonstrate high sensitivity, their specificity remains limited (20,24). Treatment for CNS infiltration involves systemic chemotherapy capable of reaching the CNS, augmented by intrathecal chemotherapy and radiotherapy (25–27).

Despite their potential efficacy, these approaches are associated with relatively high recurrence rates and adverse effects (28–30). Moreover, the unique CNS microenvironment serves as a reservoir for AML cells, influencing disease biology and chemotherapy resistance, which contributes to BM relapse and reduced survival rates (31,32). This emphasizes the necessity of deeper understanding of the specific pathways and mechanisms underlying CNS involvement in AML.

The infiltration of AML cells into the CNS involves two primarily phases: Escaping the BM and migrating to the CNS (1). AML cells must overcome two barriers-the marrow-blood barrier (MBB) and the brain barrier to reach the CNS. This process resembles leukocytes migrating from the BM into the vasculature and subsequently into the tissues, relying on interactions between migratory cells, vascular endothelial cells and stromal cells. However, the mechanisms regulating the entry of AML cells and leukocytes into the vasculature and CNS differ. In normal hematopoiesis, myeloid progenitor cells, which have not yet matured into myeloid cells, encounter obstacles crossing into the CNS, an immune-privileged organ. By contrast, AML cells, originating from a single myeloid progenitor cells with mutations, acquire malignant traits that facilitate invasion and migration (2). Additionally, changes in the vascular anatomy within the tumor microenvironment during AML development enable AML cells to escape from the BM (3,4).

The traversal of AML cells through the MBB and brain barrier is driven by chemotactic factors, governed by cell adhesion molecules (CAM), and facilitated by proteolytic enzymes (33,34). Previous literature was analyzed to elucidate the pathways and mechanisms by which AML cells evade the BM and migrate to the CNS. Additionally, similarities and differences in escape mechanisms of AML cells and leukocytes from the BM are discussed. The present comprehensive overview aimed to assist clinicians and researchers in developing novel diagnostic and therapeutic strategies. To identify relevant studies, PubMed was searched for original articles and reviews up to May 1, 2024, using the search terms ‘AML’, ‘CNS’, ‘peripheral blood’ and ‘therapeutic strategies’. Studies were eligible if they met the following criteria: i) Provided detailed descriptions of the pathways and molecular mechanisms through which AML cells escape from the BM and infiltration into the CNS; ii) therapeutic approaches targeting molecules associated with AML cells' egress from BM and entry into the CNS; iii) were written in English and published in peer-reviewed journals. Studies were excluded if they solely identified an association of a molecule with increased leukocyte count in patients with AML or CNS infiltration without validation in vivo or in vitro. Additionally, conference articles lacking original research and studies for which full-text access was unavailable were excluded.

2. The escape from the BM

Anatomical structures involved in AML cells' escape

AML cells originate within the extravascular niche, necessitating their traversal through the MBB to access the bloodstream. The hematopoietic blood supply in the BM primarily derives from nutrient arteries, which return via nutrient veins situated in the central trabecular bone of long bones (Fig. 1A) (35). Within the BM, nutrient arteries bifurcate into arterioles, which further subdivide into capillaries and sinusoidal capillaries, also referred to as blood sinuses (Fig. 1B) (36). These blood sinuses constitute the MBB, a barrier delineating the hematopoietic compartment from the bloodstream (37). The MBB is composed of endothelial cells, a basement membrane and adventitial cells, sequentially arranged from the interior outward (Fig. 1C and D) (38).

Endothelial cells form a monolayer lining the inner wall of blood sinuses essential for cellular trafficking within the MBB. They connect via tight junctions and exhibit transient fenestrations that permit cell passage (38). The subendothelial basement membrane comprises a network of laminin and type IV collagen interacting with other extracellular matrix (ECM) molecules such as collagen and fibronectin to facilitate vascular wall development (39,40). Unlike typical basement membranes, the blood sinus basement membrane is discontinuous and lacks a reticular structure. Additionally, it contains an exceptionally high concentration of sulfated glycosaminoglycans, facilitating communication and adhesion between hematopoietic cells and vascular endothelial cells (41). Adventitial cells form the outermost layer of the blood sinus (42), partially encircling the outer wall with an adventitial sheath covering ~2/3 of its surface.

The adventitial cell coverage ratio (ACCR) represents the proportion of adventitial cells enveloping endothelial cells. A reduced ACCR signifies an increased propensity for AML cells to enter the bloodstream. Advanced morphometric analysis demonstrated a substantial decline in ACCR, from 53 to 14%, in a transplantable monomyelocytic leukemia murine model, with no alterations in the endothelial cell area or perimeter (43). Transmission electron microscopy revealed that ACCR dropped to 40% among 24 untreated patients with various forms of acute leukemia, compared with controls. Furthermore, no abnormal translocation of leukemia cells at intercellular junctions within blood sinuses was observed (44,45).

In the blood sinuses of patients with AML, leukemia cells coexist with normal hematopoietic cells. The marrow stroma also comprises stromal cells, soluble molecules and ECM components (46). Specific ECM proteins of leukemic cells can bind leukocyte-specific proteins, thereby limiting leukocyte migration from the BM (38).

Mechanisms involved in AML cells' escape

The traversal of the MBB by AML cells hinges on alterations surface chemokine receptor expression and adhesion molecules profiles. Endothelial cells critically mediate interaction between AML cells and the barrier. This section delves into intrinsic changes within AML cells and their interactions with the tumor microenvironment, particularly examining how these interactions facilitate BM escape.

Chemokines and their receptor, such as stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12 (CXCL12) and chemokine receptor 4 (CXCR-4) (47), are fundamental for the AML cells' egress from the BM. A previous study by Möhle et al (48) demonstrated that CXCR-4 expression modulates AML cells' traversal of the MBB through the chemotactic response to SDF-1. Specifically, AML subtypes M4 and M5, marked by monocytic differentiation, show heightened CXCR4 expression, enabling SDF-1 to induce rapid intracellular calcium flux and significantly enhance extramedullary migration (49). Nonetheless, the mechanisms governing SDF-1 upregulation and its cellular sources remain to be elucidated.

Cluster of differentiation 31 (CD31), or platelet endothelial cell adhesion molecule 1, is a member of the immunoglobulin superfamily (50). Present in both endothelial and AML cells, CD31 significantly contributes to trans-endothelial migration via homophilic binding (51). Its expression is markedly elevated in the M4/M5 subgroups, which exhibit high metastatic potential (50). Cluster of differentiation 38 (CD38), a transmembrane glycoprotein, is also expressed on AML cells (52,53). The interactions of CD31 with endothelial cells and CD38 with hyaluronic acid in the ECM influence the equilibrium between AML cells release and retention. A CD31/CD38 ratio exceeding 1 facilitates homophilic interactions with the vasculature, enhancing trans-endothelial migration. Conversely, a ratio below 1 promotes retention of AML cells in the BM via interactions with hyaluronic acid (54).

Elevated levels of lymphocyte function-associated antigen-1 (LFA-1), an integrin superfamily member, can facilitate the migration of normal immature progenitor cells (CD34+ precursor cells) into the bloodstream (55,56), likely by enhancing their trans-endothelial migration (57,58). LFA-1 acts as the primary receptor for intercellular CAM-1 (ICAM-1, CD54). During leukocytosis, AML cells induce endothelial cells to secrete ICAM-1, thereby enhancing adhesion via LFA-1 (59). Notably, LFA-1 expression is significantly elevated in patients with AML with extramedullary organ infiltration compared with those without, yet no substantial difference in LFA-1 expression is evident between AML cells in the BM microenvironment and those in the bloodstream. A previous study, however, suggested that LFA-1 may not be crucial for the release of AML cells into the bloodstream (60).

The heterodimeric integrin very late antigen 4, consisting of CD29 subunits, is another integrin family member. Vascular CAM-1 (VCAM-1), an immunoglobulin superfamily member, is primarily a membrane-bound transmembrane type I sialic acid glycoprotein with multiple Ig-like domains connected by disulfide bonds (61). Soluble VCAM-1, predominantly produced in response to pro-inflammatory cytokines in the vascular endothelium, facilitates the recruitment, adhesion and migration of monocytes, lymphocytes, eosinophils and basophils (62,63). Although AML cells can adhere to endothelial cells through the rate-limiting α-chain of the CD49d/CD29 integrin heterodimer very late antigen-4 (CD49d)/VCAM-1 adhesion mechanism, CD49d expression is not essential for AML cell release from the BM (60).

L-selectin (CD62L), a CAM in the selectin family, is highly expressed on CD34+ precursor AML cells, contrasting with its low expression on normal CD34+ cells. This expression contributes to aggregation of AML cells in peripheral blood (55,64).

Matrix metalloproteinases (MMPs), zinc (II)-dependent endopeptidases, are secreted by AML cells and the tumor microenvironment to remodel the ECM (65,66). By facilitating ECM degradation, MMPs enable the extensive release of AML cells into the bloodstream, resulting in widespread infiltration (67). The persistent expression of tumor necrosis factor-α in AML cells elevates MMP-9 expression, which is crucial for their early release into circulation (68). MMP-9 and/or MMP-2 mRNA were expressed in all samples from patients with AML and AML cell lines examined by Janowska-Wieczorek et al (69) but not in normal CD34+ precursor cells. Interestingly, mature monocytes in the BM express and secrete MMP-9, suggesting its potential role in monocyte migration into the bloodstream (69). Consequently, AML and white blood cells may employ similar mechanisms for entering the bloodstream.

Elastase, a protease degrading elastin in the ECM, is excessively overexpressed on the cell surface of patients with AML and correlates with AML cell counts in the circulation. SDF-1 can upregulate the expression of cell surface elastase in AML cells. Inhibition of cell surface elastase diminishes migration and adhesion of AML cell lines in vitro, while administration of elastase inhibitors in AML mice significantly reduces circulating AML cell levels (70).

Chemokine (SDF-1), CAMs (CD31/CD38 ratio, CD62L), MMPs and elastase have been corroborated by in vitro and in vivo experiments for their roles in AML cells' egress from the bone marrow. However, the role of CAMs (LFA-1, CD49d) remains contentious and warrants further investigation. The release of AML cells into the bloodstream is influenced by their affinity for two blood sinuses components: Endothelial cells and the ECM. AML cells with higher endothelial affinity are more likely to enter the bloodstream, while those with a higher ECM affinity remain anchored within the blood sinus. Adhesion molecules (for example, CD31) and chemokines (for example, CXCL12) facilitate AML cells adhesion and migration, while elevated levels of proteases (such as MPP family) can degrade the ECM to enable cell movement (Fig. 2).

3. AML cell infiltration of the CNS

Potential routes and anatomical structures involved

Tumors metastasize primarily through four routes: Lymphatic metastasis, hematogenous metastasis, implantation metastasis and direct extension. Conventionally, AML cells are considered to enter the CNS predominantly through hematogenous metastasis, necessitating traversal of the brain barrier. However, a previous study suggested that AML cells may also infiltrate via the bridging veins (1). Although the CNS was once considered to possess immune privilege, recent insights into its lymphatic system challenge this view, potentially offering a more comprehensive understanding of how AML cells infiltrate into the CNS.

Hematogenous metastasis

The CNS receives its blood supply from the vertebral and internal carotid arteries. The interface between the vasculature and the structural components of the CNS forms the brain barrier, encompassing the blood-brain barrier (BBB), the blood-leptomeningeal barrier (BLMB) and the blood-CSF barrier (BCSFB) (71). This intricate system regulates the physiological entry of molecules and cells into the CNS, maintaining internal stability.

The BBB, located between the vasculature and the CNS, consists of three primary layers arranged from inner to outer: i) Capillary endothelial cells; ii) capillary basement membrane; and iii) astrocytes. The endothelial cells are tightly joined and lack fenestrations, limiting the passage of large molecules. However, in specific CNS regions, such as the circumventricular organs, pineal gland and neurohypophysis, the capillary endothelial cells have fenestrations and are connected by gap junctions, permitting the free movement of proteins and large molecules (Fig. 3, route 1). Histopathological evidence suggests that in advanced CNS involvement, AML cells may proliferate along perivascular spaces (or Virchow-Robin spaces) and infiltrate the brain parenchyma (72).

The BLMB comprises a layer of leptomeningeal cells encircling microvessels within the subarachnoid space (73). AML cells infiltrate the leptomeninges through trans-endothelial migration or direct vascular endothelium disruption (74). Once within, AML cells may infiltrate brain parenchyma by invading the perivascular spaces (74) (Fig. 3, route 2).

The BCSFB, situated in the choroid plexus of the brain ventricles, separates blood from the CSF. It is formed by choroid plexus epithelial cells interconnected by tight junctions and postcapillary venules of the meningeal microvasculature. However, choroid plexus capillary endothelial cells have fenestrations, providing some permeability. CSF is produced in the choroid plexuses of each brain ventricle, flowing from the lateral to the third ventricle, passes through the cerebral aqueduct of Sylvius into the fourth ventricle, and merging with the CSF generated by the third and fourth ventricles. It then enters the subarachnoid space through the median aperture (Magendie's foramen) of the fourth ventricle and is absorbed by the Pacchionian granulations (arachnoid granulations) into the dural venous sinuses, returning to the bloodstream. Leukemic cells can cross the BCSFB to enter the CSF (Fig. 3, Route 3).

Invasion through bridging veins, analogous to direct extension

The CNS is protected by four anatomical layers: Pia mater, arachnoid mater, dura mater and the cranial and vertebral bones, arranged from innermost to outermost. The BM within cranial and vertebral bones is hypothesized to serve as a crucial reservoir of marrow cells supporting the CNS. These reservoirs directly supply monocytes and neutrophils to the brain and spinal cord through dura mater-BM connections formed by vascular bridging veins (75), potentially serving as routes for infiltration of AML cells into the CNS (Fig. 3, Route 4).

A study examining 31 cases of CNS involvement in acute leukemia reported frequent dural infiltration, whereas arachnoid infiltration without dural involvement was relatively rare, occurring in only 9% of cases. Anatomical evidence robustly supports the theory that AML cells infiltrate the CNS through veins connecting the dura mater and BM (76).

Lymphatic metastasis

The CNS was considered an immune-privileged site; however, previous murine studies have identified a lymphatic system within the dura mater that drains CSF from deep brain parenchyma, revealing new communication routes between the CNS and the circulatory system (77,78). This unique dural lymphatic vascular network extends along the dural sinuses, providing a unidirectional absorption and transport system (79). Additionally, the CNS contains the glymphatic system, which, unlike traditional lymphatic systems, comprises perivascular spaces between capillaries and astrocytes. CFS enters through perivascular spaces around arterial vessels, exits around venous vessels, and subsequently joins the dural lymphatic network near the dural sinuses (80).

Typically, CSF flow through the lymphatic system is unidirectional; however, retrograde flow can occur if the distal lymphatic system is obstructed, leading to the accumulation of cells, such as AML cells, in the lymphatic system and their subsequent entry into the CNS. This retrograde flow contributes to the increased risk of CNS infiltration in patients with high white blood cell counts, who are more susceptible to venous and lymphatic stasis, a common complication in leukocytosis (Fig. 3, Route 5).

Other routes

AML cells infiltrate the CNS through multiple routes. One involves traversing nerve roots through neural foramina into the epidural space. Another route is the infiltration of AML cells into the CNS during intracerebral hemorrhage. Additionally, CNS infiltration can occur iatrogenically when AML cells are introduced into the CFS during LP procedures (28).

Mechanisms of AML cells' infiltration

Current research on AML cells entry into the CNS focuses primarily on their traversal of the BBB. This discussion emphasizes this aspect. Interactions between AML and endothelial cells not only facilitate migration of AML cells but also induce endothelial cells necroptosis, thereby promoting AML cells' extravasation (81). Furthermore, astrocytes, as critical component of the BBB, significantly influence AML cell infiltration into the CNS.

Endothelial cells and astrocytes, components of the BBB, express ICAM-1 and VCAM-1, respectively, facilitating AML cell transmigration through interacting with LFA-1 and CD49d on AML cells (82,83). Inhibiting the VCAM1-CD49d pathway diminishes AML cells invasion into the brain and decelerates disease progression. Furthermore, the loss of interferon regulatory factor 7 promotes VCAM1-CD49d-mediated intracranial invasion by downregulating TG-interacting factor 1 (84). The expression of cluster of differentiation 56 on endothelial cells also plays a crucial role in AML cell passage through the BBB (74) and is associated with CNS relapse (85,86).

Immunoglobulin-like receptor B4 (LILRB4), part of the leukocyte Ig-like receptor B subfamily, is crucial for CNS infiltration by AML cells (87). Antibody blockade of LILRB4 can reduce CNS infiltration. The APOE protein (APOE-POPC) binds to LILRB4, suppressing immune responses in patients with AML and facilitating dissemination of AML cells (88). A study involving 56 patients with AML revealed that 91% of those with CNS infiltration exhibited high LILRB4 expression, compared with 38% without CNS involvement. Additionally, LILRB4 expression is elevated in M4 and M5 AML subtypes, which are more susceptible to CNS infiltration (89). The significant role of LILRB4 in CNS infiltration highlights its potential as a target for antibody-drug conjugates designed to eliminate AML cells and reduce CNS involvement (87).

Macrophage-secreted MMP-9 disrupts the vascular endothelial cells of the BBB, promoting secondary intracranial infections and brain lesions (90). Furthermore, MMP-mediated loss of endothelial integrity facilitates AML cells' extravasation into tissues (91,92). Given their ability to compromise the BBB and endothelial cells and their high expression in AML, MMPs likely play a significant role in CNS invasion.

Mutations in exon 18 of DNMT3A (D3Amut) enhance the monocyte invasiveness and migration of AML cells, leading to meningeal leukemia in mice (93). Additionally, D3Amut induces demethylation and upregulation of the TWIST1 gene in AML cells, facilitating CNS infiltration (94). Overexpression of the human TIMP-2 gene in mice results in increased tumor formation across various organs and severe CNS infiltration (95). These mutations are prevalent in the AML subtypes M4 or M5, which are more prone to CNS infiltration (96).

In conclusion, enhanced expression of adhesion molecules facilitates the interaction between AML cells and the BBB components. Additionally, enzyme and gene mutations significantly contribute to CNS infiltration in AML (Fig. 4).

4. Relevant molecules and genes for the treatment in AML

The absence of specific surface antigens on AML cells poses a significant challenge to developing targeted therapies and cell-based treatments for AML. While the aforementioned molecules and genes involved in AML cells' escape and CNS infiltration hold potential as therapeutic targets, their clinical application has been constrained by adverse effects. Recent advancements in drug synthesis and novel delivery systems have enabled more precise targeting of these drugs, mitigating side effects. Subsequently, the present discussion delved into the practical implications and current limitations of these therapeutic strategies.

The chemokine axis CXCR4/SDF-1 serves as a potential therapeutic target in AML, with the efficacy of related inhibitors validated in both in vitro and in vivo experiments. Some inhibitors have advanced to clinical trials. In vitro studies have shown promising results in AML treatment through reducing CXCR4 expression using lipid polymer/siRNA complexes (97). Currently, CXCR4 inhibitors such as AMD3100 are under investigation in Phase I/II clinical trials combined with chemotherapy for refractory/relapsed and newly diagnosed patients with AML (98,99). Although direct evidence is lacking, targeted CXCR4 therapy may potentially reduce CNS involvement in AML. In vivo experiments have shown that the chemically synthesized CXCR4 antagonistic peptide E5, formulated as micelles (M-E5), significantly inhibits AML cells engraftment in the spleen, thereby reducing organ burden (100). Due to their widespread presence across various cells types, CAMs have been limited as targets for AML therapy. However, recent studies have opened new avenues for preclinical investigations. For instance, combining all-trans retinoic acid with daratumumab, an anti-CD38 antibody-conjugated polymer sulfate deoxycholic acid, effectively eliminated circulating leukemia cells and reduced organ invasion in AML models with low CD38 expression (101,102). Additionally, low and non-toxic doses of the microtubule destabilizer combretastatin-A4-phosphate (CA4P) downregulated CAM (VCAM-1), targeting circulating leukemia cells without inducing hematologic toxicity, providing an effective approach for treating refractory organ-infiltrative leukemia (103).

LILRB4, extensively expressed on monocyte AML cells, represents a promising tumor-associated antigen for immunotherapeutic targeting. A novel anti-LILRB4 CAR-T cell, exhibiting high affinity and specificity, has shown potent cytotoxicity against LILRB4-positive AML cells in both in vitro and in vivo models (104).

MMPs, as potential therapeutic targets for various diseases, have attracted substantial research interest. These enzymes are pivotal in extracellular matrix degradation and are regarded as primary drivers of cancer invasion and metastasis. Consequently, MMPs have become significant targets in anticancer drug development (105–108). Studies have explored the in vitro anti-AML activity of METVAN [bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV); VO(SO(4))(Me(2)-Phen)(2)], which inhibits the expression and gelatinolytic activity of MMP-2 and MMP-9 proteins, thereby inducing apoptosis in AML cells (109).

DNMT3A, frequently mutated in AML, functions as a DNA cytosine methyltransferase and a key epigenetic driver of transcriptional silencing, commonly dysregulated in cancer. Hypomethylating agents, such as the cytidine analogs decitabine and azacitidine, have demonstrated clinical benefits in hematologic malignancies. However, their significant toxicity to normal blood cells restricts clinical dosing (110). A targeted delivery system using endogenous anti-CD33 antibody-fused protein conjugates to deliver DNMT3A-targeting siRNA into AML cells has been recently investigated, showing therapeutic efficacy both in vitro and in vivo (111).

Advancements in drug synthesis and delivery technologies have validated the therapeutic roles of relevant molecules and genes in AML through in vitro and in vivo experiments, and preclinical studies. While existing research primarily addresses extramedullary infiltration, specific data on inhibiting CNS involvement in AML remains scarce.

5. Conclusion and future considerations

The objective of the present review was to enhance the understanding of AML cells' invasion into the CNS, a significant concern due to its association with relapse and mortality in patients with AML. Preventing CNS relapse is a key component of AML treatment, yet it remains a formidable issue. Elucidating the molecular mechanisms of CNS infiltration in AML can pave the way for innovative diagnostic and therapeutic strategies. AML cells migrate to the bloodstream through sinusoids under the influence of chemotactic factors, CAMs, MMPs and elastase. They subsequently cross the BBB into the CNS due to gene mutations, CAMs, MMPs and LILRB, or infiltrate the CNS via bridging veins and lymphatics. The present review highlights the role of CAMs and gene mutations in CNS infiltration, suggesting that immunotherapy and targeted therapy could offer effective therapeutic options. However, the precise pathways and mechanisms underlying AML cells' escape from the BM and CNS invasion remain partially understood. Current therapeutic approaches for CNS involvement in AML primarily rely on systemic chemotherapy, intrathecal chemotherapy and radiotherapy, which continue to exhibit high recurrence rates and side effects due to the lack of molecularly targeted agents and advanced cellular therapies. Further research is imperative to clarify the routes and regulatory mechanisms of AML cells' egress from the BM and CNS invasion. Additionally, detecting gene mutations in AML cells within the CSF could provide a novel and more effective diagnostic method. Future advances in drug synthesis and delivery systems hold promise for developing therapies targeting CAMs, MMPs, elastase and gene mutations, thereby offering new treatment options for patients with AML with CNS involvement.

Acknowledgements

Not applicable.

Availability of data and materials

Not applicable.

Authors' contributions

LC wrote the original draft. PZ wrote and reviewed the manuscript. HT performed investigation. GC conducted validation. JX performed visualization. XY supervised the study. XL conceptualized the study. All authors read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

AML acute myeloid leukemia

CNS central nervous system

BM bone marrow

CSF cerebrospinal fluid

LP lumbar puncture

MBB marrow-blood barrier

CAM cell adhesion molecules

ECM extracellular matrix

ACCR adventitial cell coverage ratio

SDF-1 stromal cell-derived factor 1

CXCL12 C-X-C motif chemokine 12

CXCR-4 chemokine receptor 4

CD31 cluster of differentiation 31

CD38 cluster of differentiation 38

LFA-1 lymphocyte function associated antigen-1

ICAM-1 intercellular CAM-1

VCAM-1 vascular CAM-1

CD49d the rate-limiting α-chain of the CD49d/CD29 integrin heterodimer very late antigen-4

MMP-9 matrix metalloproteinase-9

BBB blood-brain barrier

BLMB blood-leptomeningeal barrier

BCSFB blood-CSF barrier

LILRB4 immunoglobulin-like receptor B4

Figure 1. Anatomical structures of sinusoids. (A) Blood supply in the bone marrow. (B) Sinusoid's location. (C and D) The marrow-blood barriers of patients with AML and healthy individuals. The adventitial cell cover rate is reduced in patients with AML. AML, acute myeloid leukemia.

Figure 2. Escape mechanisms of AML cells. This figure illustrates two distinct processes: On the left side of the dotted lines-a mechanism underlying the capture of the AML cells within the sinusoid. On the right side of the dotted lines-a mechanism facilitating the transportation of AML cells into circulation. AML, acute myeloid leukemia; ECM, extracellular matrix; CD38, cluster of differentiation 38; CD49d, the rate-limiting α-chain of the CD49d/CD29 integrin heterodimer very late antigen-4; VCAM-1, vascular cell-adhesion molecule 1; MMP-9, matrix metalloproteinase-9; CD31, cluster of differentiation 31; LFA-1, lymphocyte function associated antigen-1; ICAM-1, intercellular cell adhesion molecule-1; SDF-1, stromal cell-derived factor 1; CXCR-4, chemokine receptor 4.

Figure 3. Routes and anatomical structures potentially involved in infiltration of the CNS. Green arrow: Routes of acute myeloid leukemia cell infiltration into the CNS. Orange arrow: Direction of the CSF influx. Route 1: Through the blood-brain barrier (1). Route 2: Through the blood-leptomeningeal barrier (2). Route 3: Through the blood-CSF barrier (3). Route 4: Through the bridging veins (4). Route 5: Through the dural lymphatic vessels (5). CNS, central nervous system; CSF, cerebrospinal fluid.

Figure 4. Mechanisms of the central nervous system exploited by AML cells. AML, acute myeloid leukemia; APOE-POPC, liposome-reconstituted APOE protein; LILRB4, immunoglobulin-like receptor B4; D3Amut, genetic mutation in exon 18 of DNMT3A; TWIST1, TWIST1 gene; TIMP-2, TIMP-2 gene; IRF7, interferon regulatory factor 7; TGIF-1, TG-interacting factor 1; CD56, cluster of differentiation 56. MMPs, matrix metalloproteinases; CD49d, rate-limiting α-chain of the CD49d/CD29 integrin heterodimer very late antigen-4; VCAM-1, vascular cell-adhesion molecule 1; LFA-1, lymphocyte function-associated antigen-1; ICAM-1, intercellular cell adhesion molecule-1.
==== Refs
References

1 Korn C Méndez-Ferrer S Myeloid malignancies and the microenvironment Blood 129 811 822 2017 10.1182/blood-2016-09-670224 28064238
2 Arber DA Orazi A Hasserjian R Thiele J Borowitz MJ Le Beau MM Bloomfield CD Cazzola M Vardiman JW The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391 2405 2016 10.1182/blood-2016-03-643544 27069254
3 Munker R Labopin M Esteve J Schmid C Mohty M Nagler A Mixed phenotype acute leukemia: Outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT Haematologica 102 2134 2140 2017 10.3324/haematol.2017.174441 28971902
4 Sas V Blag C Zaharie G Puscas E Lisencu C Andronic-Gorcea N Pasca S Petrushev B Chis I Marian M Transient leukemia of Down syndrome Crit Rev Clin Lab Sci 56 247 259 2019 10.1080/10408363.2019.1613629 31043105
5 Dima D Oprita L Rosu AM Trifa A Selicean C Moisoiu V Frinc I Zdrenghea M Tomuleasa C Adult acute megakaryoblastic leukemia: Rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts Onco Targets Ther 10 5047 5051 2017 10.2147/OTT.S146973 29089774
6 Gafencu GA Tomuleasa CI Ghiaur G PARP inhibitors in acute myeloid leukaemia therapy: How a synthetic lethality approach can be a valid therapeutic alternative Med Hypotheses 104 30 34 2017 10.1016/j.mehy.2017.05.015 28673584
7 Johnston DL Alonzo TA Gerbing RB Aplenc R Woods WG Meshinchi S Gamis AS Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group Pediatr Blood Cancer 64 10 2017 10.1002/pbc.26612 28423223
8 Constantinescu C Bodolea C Pasca S Teodorescu P Dima D Rus I Tat T Achimas-Cadariu P Tanase A Tomuleasa C Einsele H Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician J Clin Med 8 884 2019 10.3390/jcm8060884 31226876
9 Goulart H Sastow D Moshier E Martin L Mascarenhas J Tremblay D Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement Leuk Res 137 107452 2024 10.1016/j.leukres.2024.107452 38335816
10 Alakel N Stölzel F Mohr B Kramer M Oelschlägel U Röllig C Bornhäuser M Ehninger G Schaich M Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia Cancer Manag Res 9 97 102 2017 10.2147/CMAR.S125259 28435324
11 Cheng CL Li CC Hou HA Fang WQ Chang CH Lin CT Tang JL Chou WC Chen CY Yao M Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults BMC Cancer 15 344 2015 10.1186/s12885-015-1376-9 25934556
12 Felix A Leblanc T Petit A Nelkem B Bertrand Y Gandemer V Sirvent A Paillard C Schmitt C Rohrlich PS Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02 J Pediatr Hematol Oncol 40 43 47 2018 10.1097/MPH.0000000000001034 29189507
13 Ganzel C Lee JW Fernandez HF Paietta EM Luger SM Lazarus HM Cripe LD Douer D Wiernik PH Rowe JM CNS involvement in AML at diagnosis is rare and does not affect response or survival: Data from 11 ECOG-ACRIN trials Blood Adv 5 4560 4568 2021 10.1182/bloodadvances.2021004999 34597373
14 Jabbour E Guastad Daver N Short NJ Huang X Chen HC Maiti A Ravandi F Cortes J Abi Aad S Garcia-Manero G Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia Am J Hematol 92 924 928 2017 10.1002/ajh.24799 28556489
15 Del Principe MI Buccisano F Soddu S Maurillo L Cefalo M Piciocchi A Consalvo MI Paterno G Sarlo C De Bellis E Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome Semin Hematol 55 209 214 2018 10.1053/j.seminhematol.2018.02.006 30502849
16 Bojsen-Møller M Nielsen JL CNS involvement in leukaemia. An autopsy study of 100 consecutive patients Acta Pathol Microbiol Immunol Scand A 91 209 216 1983 6575578
17 Paul S Short NJ Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management Curr Oncol Rep 24 427 436 2022 10.1007/s11912-022-01220-4 35141858
18 Virijevic M Kraguljac-Kurtovic N Mitrovic M Jakovic L Bukumuric Z Pantic N Sabljic N Pravdic Z Cvetkovic M Knezevic V Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia Hematol Oncol 42 e3253 2024 10.1002/hon.3253 38536200
19 Bar M Tong W Othus M Loeb KR Estey EH Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation Biol Blood Marrow Transplant 21 546 551 2015 10.1016/j.bbmt.2014.11.683 25545726
20 Bento LC Correia RP Alexandre AM Nosawa ST Pedro EC Vaz ADC Schimidell D Fernandes GBP Duarte CAS Barroso RS Bacal NS Detection of Central Nervous System Infiltration by Myeloid and Lymphoid Hematologic Neoplasms Using Flow Cytometry Analysis: Diagnostic Accuracy Study Front Med (Lausanne) 5 70 2018 10.3389/fmed.2018.00070 29876349
21 Ranta S Palomäki M Levinsen M Taskinen M Abrahamsson J Hasle H Jahnukainen K Heyman M Harila-Saari A Nordic Society of Pediatric Haematology Oncology (NOPHO) Presenting features and imaging in childhood acute myeloid leukemia with central nervous system involvement Pediatr Blood Cancer 64 2017 10.1002/pbc.26182
22 Reid JH Perissinotti AJ Benitez L Bixby DL Burke P Pettit K Marini BL Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis Leuk Lymphoma 61 862 868 2020 10.1080/10428194.2019.1691199 31739707
23 Berg S Nand S Neurological Complications of the Leukemias Across the Ages Curr Neurol Neurosci Rep 17 13 2017 10.1007/s11910-017-0726-1 28229399
24 Chamberlain MC Glantz M Groves MD Wilson WH Diagnostic tools for neoplastic meningitis: Detecting disease, identifying patient risk, and determining benefit of treatment Semin Oncol 36 (4 Suppl 2) S35 S45 2009 10.1053/j.seminoncol.2009.05.005 19660682
25 Thakkar JP Kumthekar P Dixit KS Stupp R Lukas RV Leptomeningeal metastasis from solid tumors J Neurol Sci 411 116706 2020 10.1016/j.jns.2020.116706 32007755
26 Duzova A Bakkaloglu A Central nervous system involvement in pediatric rheumatic diseases: Current concepts in treatment Curr Pharm Des 14 1295 1301 2008 10.2174/138161208799316339 18537653
27 Ebadi M Morse M Gooley T Ermoian R Halasz LM Lo SS Yang JT Blau MH Percival ME Cassaday RD Craniospinal irradiation for CNS leukemia: Rates of response and durability of CNS control J Neurooncol 166 351 357 2024 10.1007/s11060-023-04501-5 38244173
28 Siegal T Benouaich-Amiel A Bairey O Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities Blood Rev 53 100910 2022 10.1016/j.blre.2021.100910 34836656
29 Chen Q Zhu XL Zhao X Liu X Fu HX Zhang YY Chen YH Mo XD Han W Chen H Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Ann Hematol 100 505 516 2021 10.1007/s00277-020-04380-0 33389025
30 Hu J Su A Liu X Tong Z Jiang Q Yu J Effects of D-CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting-state functional magnetic resonance imaging study Eur J Neurosci 59 119 131 2024 10.1111/ejn.16191 37969020
31 Zhang C Zhong JF Zhang X Revealing the molecular mechanism of central nervous system leukemia with single-cell technology Crit Rev Oncol Hematol 153 103046 2020 10.1016/j.critrevonc.2020.103046 32650214
32 Si M Jiao X Li Y Chen H He P Jiang F The role of cytokines and chemokines in the microenvironment of the blood-brain barrier in leukemia central nervous system metastasis Cancer Manag Res 10 305 313 2018 10.2147/CMAR.S152419 29483784
33 Nourshargh S Alon R Leukocyte migration into inflamed tissues Immunity 41 694 707 2014 10.1016/j.immuni.2014.10.008 25517612
34 Ley K Laudanna C Cybulsky MI Nourshargh S Getting to the site of inflammation: The leukocyte adhesion cascade updated Nat Rev Immunol 7 678 689 2007 10.1038/nri2156 17717539
35 Maloney MA Forsyth RP Patt HM Bone marrow blood flow after marrow removal or nutrient vessel ligation Proc Soc Exp Biol Med 135 871 873 1970 10.3181/00379727-135-35161 5486725
36 Kusumbe AP Ramasamy SK Adams RH Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone Nature 507 323 328 2014 10.1038/nature13145 24646994
37 Tavassoli M The marrow-blood barrier Br J Haematol 41 297 302 1979 10.1111/j.1365-2141.1979.tb05862.x 371662
38 Petrides PE Dittmann KH How do normal and leukemic white blood cells egress from the bone marrow? Morphological facts and biochemical riddles Blut 61 3 13 1990 10.1007/BF01739426 2201412
39 Wight TN Cell biology of arterial proteoglycans Arteriosclerosis 9 1 20 1989 10.1161/01.ATV.9.1.1 2643420
40 Owen M Marrow stromal stem cells J Cell Sci Suppl 10 63 76 1988 10.1242/jcs.1988.Supplement_10.5 3077943
41 Inoue S Osmond DG Basement membrane of mouse bone marrow sinusoids shows distinctive structure and proteoglycan composition: A high resolution ultrastructural study Anat Rec 264 294 304 2001 10.1002/ar.1166 11596011
42 Bentley SA Foidart JM Some properties of marrow derived adherent cells in tissue culture Blood 56 1006 1012 1980 10.1182/blood.V56.6.1006.bloodjournal5661006 7002230
43 Leonardi GP Manthos M Orlic D Lobue J Morphometric analysis of bone marrow sinus cell elements after induction of monomyelocytic leukemia in BALB/c mice Anat Rec 224 331 335 1989 10.1002/ar.1092240302 2782618
44 Kuto F Nagaoka T Watanabe Y Hayashi M Horasawa Y Hirasawa Y Tokuhiro H Chronic myelocytic leukemia: Ultrastructural histopathology of bone marrow from patients in the chronic phase Ultrastruct Pathol 6 307 317 1984 10.3109/01913128409018589 6592869
45 Nagaoka T Kuto F Watanabe Y Fujino Y Hirasawa Y Tokuhiro H Bone marrow sinus and cell egress in human leukaemia: a morphometric study of core biopsies using wide-field electron microscopy Br J Haematol 63 737 747 1986 10.1111/j.1365-2141.1986.tb07557.x 3460628
46 Gordon MY Extracellular matrix of the marrow microenvironment Br J Haematol 70 1 4 1988 10.1111/j.1365-2141.1988.tb02425.x 3052566
47 Oberlin E Amara A Bachelerie F Bessia C Virelizier JL Arenzana-Seisdedos F Schwartz O Heard JM Clark-Lewis I Legler DF The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 Nature 382 833 835 1996 10.1038/382833a0 8752281
48 Möhle R Bautz F Rafii S Moore MA Brugger W Kanz L The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1 Blood 91 4523 4530 1998 10.1182/blood.V91.12.4523 9616148
49 Möhle R Schittenhelm M Failenschmid C Bautz F Kratz-Albers K Serve H Brugger W Kanz L Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia Br J Haematol 110 563 572 2000 10.1046/j.1365-2141.2000.02157.x 10997965
50 Newman PJ Berndt MC Gorski J White GC II Lyman S Paddock C Muller WA PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily Science 247 1219 1222 1990 10.1126/science.1690453 1690453
51 Muller WA Weigl SA Deng X Phillips DM PECAM-1 is required for transendothelial migration of leukocytes J Exp Med 178 449 460 1993 10.1084/jem.178.2.449 8340753
52 Howard M Grimaldi JC Bazan JF Lund FE Santos-Argumedo L Parkhouse RM Walseth TF Lee HC Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38 Science 262 1056 1059 1993 10.1126/science.8235624 8235624
53 Nishina H Inageda K Takahashi K Hoshino S Ikeda K Katada T Cell surface antigen CD38 identified as ecto-enzyme of NAD glycohydrolase has hyaluronate-binding activity Biochem Biophys Res Commun 203 1318 1323 1994 10.1006/bbrc.1994.2326 8093047
54 Gallay N Anani L Lopez A Colombat P Binet C Domenech J Weksler BB Malavasi F Herault O The role of platelet/endothelial cell adhesion molecule 1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells Cancer Res 67 8624 8632 2007 10.1158/0008-5472.CAN-07-0402 17875702
55 Dercksen MW Gerritsen WR Rodenhuis S Dirkson MK Slaper-Cortenbach IC Schaasberg WP Pinedo HM von dem Borne AE van der Schoot CE Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation Blood 85 3313 3319 1995 10.1182/blood.V85.11.3313.bloodjournal85113313 7538823
56 Torensma R Raymakers RA van Kooyk Y Figdor CG Induction of LFA-1 on pluripotent CD34+ bone marrow cells does not affect lineage commitment Blood 87 4120 4128 1996 10.1182/blood.V87.10.4120.bloodjournal87104120 8639769
57 Möhle R Moore MA Nachman RL Rafii S Transendothelial migration of CD34+ and mature hematopoietic cells: An in vitro study using a human bone marrow endothelial cell line Blood 89 72 80 1997 10.1182/blood.V89.1.72.72_72_80 8978279
58 Yong KL Watts M Shaun Thomas N Sullivan A Ings S Linch DC Transmigration of CD34+ cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31) Blood 91 1196 1205 1998 10.1182/blood.V91.4.1196 9454749
59 Zhang W Zhang X Fan X Li D Qiao Z Effect of ICAM-1 and LFA-1 in hyperleukocytic acute myeloid leukaemia Clin Lab Haematol 28 177 182 2006 10.1111/j.1365-2257.2006.00784.x 16706934
60 Liu T Liu X Xiang J Zou P Zhou J Chen Y Yu D Li C Study on the relationship between the expression of adhesion molecules and the invasiveness of acute myeloid leukemia cells Zhonghua Xue Ye Xue Za Zhi 18 29 31 1997 (In Chinese) 15622747
61 Cook-Mills JM Marchese ME Abdala-Valencia H Vascular cell adhesion molecule-1 expression and signaling during disease: Regulation by reactive oxygen species and antioxidants Antioxid Redox Signal 15 1607 1638 2011 10.1089/ars.2010.3522 21050132
62 Meigs JB Hu FB Rifai N Manson JE Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus JAMA 291 1978 1986 2004 10.1001/jama.291.16.1978 15113816
63 Dessein PH Joffe BI Singh S Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis Arthritis Res Ther 7 R634 R643 2005 10.1186/ar1717 15899050
64 Watanabe T Dave B Heimann DG Jackson JD Kessinger A Talmadge JE Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation Exp Hematol 26 10 18 1998 9430509
65 Jing M Chen X Qiu H He W Zhou Y Li D Wang D Jiao Y Liu A Insights into the immunomodulatory regulation of matrix metalloproteinase at the maternal-fetal interface during early pregnancy and pregnancy-related diseases Front Immunol 13 1067661 2023 10.3389/fimmu.2022.1067661 36700222
66 Pirillo C Birch F Tissot FS Anton SG Haltalli M Tini V Kong I Piot C Partridge B Pospori C Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness Blood Adv 6 3126 3141 2022 10.1182/bloodadvances.2021004321 35157757
67 Song JH Kim SH Cho D Lee IK Kim HJ Kim TS Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2 Int J Cancer 125 1074 1081 2009 10.1002/ijc.24386 19449375
68 Ismair MG Ries C Lottspeich F Zang C Kolb HJ Petrides PE Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: Specific involvement of TNF receptor type 1 Leukemia 12 1136 1143 1998 10.1038/sj.leu.2401042 9665201
69 Janowska-Wieczorek A Marquez LA Matsuzaki A Hashmi HR Larratt LM Boshkov LM Turner AR Zhang MC Edwards DR Kossakowska AE Expression of matrix metalloproteinases (MMP-2 and −9) and tissue inhibitors of metalloproteinases (TIMP-1 and −2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells Br J Haematol 105 402 411 1999 10.1111/j.1365-2141.1999.01352.x 10233411
70 Tavor S Petit I Porozov S Goichberg P Avigdor A Sagiv S Nagler A Naparstek E Lapidot T Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice Blood 106 2120 2127 2005 10.1182/blood-2004-12-4969 15941909
71 Shechter R London A Schwartz M Orchestrated leukocyte recruitment to immune-privileged sites: Absolute barriers versus educational gates Nat Rev Immunol 13 206 218 2013 10.1038/nri3391 23435332
72 Price RA Histopathology of CNS leukemia and complications of therapy Am J Pediatr Hematol Oncol 1 21 30 1979 396790
73 Spadoni I Fornasa G Rescigno M Organ-specific protection mediated by cooperation between vascular and epithelial barriers Nat Rev Immunol 17 761 773 2017 10.1038/nri.2017.100 28869253
74 Deak D Gorcea-Andronic N Sas V Teodorescu P Constantinescu C Iluta S Pasca S Hotea I Turcas C Moisoiu V A narrative review of central nervous system involvement in acute leukemias Ann Transl Med 9 68 2021 10.21037/atm-20-3140 33553361
75 Cugurra A Mamuladze T Rustenhoven J Dykstra T Beroshvili G Greenberg ZJ Baker W Papadopoulos Z Drieu A Blackburn S Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma Science 373 eabf7844 2021 10.1126/science.abf7844 34083447
76 Azzarelli V Roessmann U Pathogenesis of central nervous system infiltration in acute leukemia Arch Pathol Lab Med 101 203 205 1977 265696
77 Louveau A Smirnov I Keyes TJ Eccles JD Rouhani SJ Peske JD Derecki NC Castle D Mandell JW Lee KS Structural and functional features of central nervous system lymphatic vessels Nature 523 337 341 2015 10.1038/nature14432 26030524
78 Aspelund A Antila S Proulx ST Karlsen TV Karaman S Detmar M Wiig H Alitalo K A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules J Exp Med 212 991 999 2015 10.1084/jem.20142290 26077718
79 Louveau A Plog BA Antila S Alitalo K Nedergaard M Kipnis J Understanding the functions and relationships of the glymphatic system and meningeal lymphatics J Clin Invest 127 3210 3219 2017 10.1172/JCI90603 28862640
80 Iliff JJ Wang M Liao Y Plogg BA Peng W Gundersen GA Benveniste H Vates GE Deane R Goldman SA A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β Sci Transl Med 4 147ra111 2012 10.1126/scitranslmed.3003748 22896675
81 Guerrini MM Okamoto K Komatsu N Sawa S Danks L Penninger JM Nakashima T Takayanagi H Inhibition of the TNF Family Cytokine RANKL prevents autoimmune inflammation in the central nervous system Immunity 43 1174 1185 2015 10.1016/j.immuni.2015.10.017 26680207
82 Maeda A Kobayashi Y Saito T Togitani K Kawahigashi N Tanosaki R Takaue Y Takenaka T Iwata N Tobinai K Central nervous system relapse with multiple brain masses in an acute promyelocytic leukemia patient treated with all-trans retinoic acid Rinsho Ketsueki 40 1081 1086 1999 (In Japanese) 10565225
83 Raanani P Shpilberg O Ben-Bassat I Extramedullary disease and targeted therapies for hematological malignancies-is the association real? Ann Oncol 18 7 12 2007 10.1093/annonc/mdl129 16790518
84 Wang H Zhang D Cui X Dai Y Wang C Feng W Lv X Li Y Wang L Ru Y Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion Oncogene 41 2303 2314 2022 10.1038/s41388-022-02233-w 35256780
85 Chang H Brandwein J Yi QL Chun K Patterson B Brien B Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome Leuk Res 28 1007 1011 2004 10.1016/j.leukres.2004.01.006 15289011
86 Yang SW Ma RJ Yuan XL Jiang L Li YL Dong XY Wang Z Zhang L Shang BJ Lei PC Zhu ZM Correlation analysis of central nervous system relapse and cell biological characteristics in acute promyelocytic leukemia Zhonghua Xue Ye Xue Za Zhi 42 517 520 2021 (In Chinese) 34384161
87 Bergstrom CP Dahiya S Chen W Zhang CC Zhu H Yan J Madanat Y Patel P Vusirkala M Ramakrishnan P The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement Leuk Res 100 106480 2021 10.1016/j.leukres.2020.106480 33285315
88 Deng M Gui X Kim J Xie L Chen W Li Z He L Chen Y Chen H Luo W LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration Nature 562 605 609 2018 10.1038/s41586-018-0615-z 30333625
89 Li Z Deng M Huang F Jin C Sun S Chen H Liu X He L Sadek AH Zhang CC LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells Cell Mol Immunol 17 272 282 2020 10.1038/s41423-019-0321-2 31700117
90 Bonoiu A Mahajan SD Ye L Kumar R Ding H Yong KT Roy I Aalinkeel R Nair B Reynolds JL MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier Brain Res 1282 142 55 2009 10.1016/j.brainres.2009.05.047 19477169
91 Stefanidakis M Karjalainen K Jaalouk DE Gahmberg CG O'Brien S Pasqualini R Arap W Koivunen E Role of leukemia cell invadosome in extramedullary infiltration Blood 114 3008 3017 2009 10.1182/blood-2008-04-148643 19636064
92 Röllig C Ehninger G How I treat hyperleukocytosis in acute myeloid leukemia Blood 125 3246 3252 2015 10.1182/blood-2014-10-551507 25778528
93 Xu J Wang YY Dai YJ Zhang W Zhang WN Xiong SM Gu ZH Wang KK Zeng R Chen Z Chen SJ DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells Proc Natl Acad Sci USA 111 2620 2625 2014 10.1073/pnas.1400150111 24497509
94 Xu J Zhang W Yan XJ Lin XQ Li W Mi JQ Li JM Zhu J Chen Z Chen SJ DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1 J Hematol Oncol 9 106 2016 10.1186/s13045-016-0337-3 27724883
95 Li ZJ Chen ZX Cen JN He J Overexpression of tissue inhibitor of metalloprotease-2 promotes proliferation and infiltration of human monocytic leukemia cells Zhonghua Yi Xue Za Zhi 86 2409 2412 2006 (In Chinese) 17156653
96 Yan XJ Xu J Gu ZH Pan CM Lu G Shen Y Shi JY Zhu YM Tang L Zhang XW Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia Nat Genet 43 309 315 2011 10.1038/ng.788 21399634
97 Landry B Gül-Uludağ H Plianwong S Kucharski C Zak Z Parmar MB Kutsch O Jiang H Brandwein J Uludağ H Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia J Control Release 224 8 21 2016 10.1016/j.jconrel.2015.12.052 26742943
98 Uy GL Rettig MP Motabi IH McFarland K Trinkaus KM Hladnik LM Kulkarni S Abboud CN Cashen AF Stockerl-Goldstein KE A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia Blood 119 3917 3924 2012 10.1182/blood-2011-10-383406 22308295
99 Peled A Tavor S Role of CXCR4 in the pathogenesis of acute myeloid leukemia Theranostics 3 34 39 2013 10.7150/thno.5150 23382784
100 Meng J Ge Y Xing H Wei H Xu S Liu J Yan D Wen T Wang M Fang X Synthetic CXCR4 antagonistic peptide assembling with nanoscaled micelles combat acute myeloid leukemia Small 16 e2001890 2020 10.1002/smll.202001890 32608185
101 Yue S An J Zhang Y Li J Zhao C Liu J Liang L Sun H Xu Y Zhong Z Exogenous antigen upregulation empowers antibody targeted nanochemotherapy of leukemia Adv Mater 35 e2209984 2023 10.1002/adma.202209984 37321606
102 Sayitoglu EC Luca BA Boss AP Thomas BC Freeborn RA Uyeda MJ Chen PP Nakauchi Y Waichler C Lacayo N AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML Leukemia 38 1246 1255 2024 10.1038/s41375-024-02255-1 38724673
103 Petit I Karajannis MA Vincent L Young L Butler J Hooper AT Shido K Steller H Chaplin DJ Feldman E Rafii S The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death Blood 111 1951 1961 2008 10.1182/blood-2007-05-089219 18024794
104 John S Chen H Deng M Gui X Wu G Chen W Li Z Zhang N An Z Zhang CC A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML Mol Ther 26 2487 2495 2018 10.1016/j.ymthe.2018.08.001 30131301
105 Jiang H Li H Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: A systematic review and meta-analysis BMC Cancer 21 149 2021 10.1186/s12885-021-07860-2 33568081
106 Bharadwaj S Sahoo AK Yadava U Editorial: Advances in the therapeutic targeting of human matrix metalloproteinases in health and disease Front Mol Biosci 10 1150474 2023 10.3389/fmolb.2023.1150474 36968281
107 Levin M Udi Y Solomonov I Sagi I Next generation matrix metalloproteinase inhibitors-Novel strategies bring new prospects Biochim Biophys Acta Mol Cell Res 1864 (11 Pt A) 1927 1939 2017 10.1016/j.bbamcr.2017.06.009 28636874
108 Winer A Adams S Mignatti P Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes Mol Cancer Ther 17 1147 1155 2018 10.1158/1535-7163.MCT-17-0646 29735645
109 Narla RK Dong Y Klis D Uckun FM Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity Clin Cancer Res 7 1094 1101 2001 11309362
110 Pappalardi MB Keenan K Cockerill M Kellner WA Stowell A Sherk C Wong K Pathuri S Briand J Steidel M Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia Nat Cancer 2 1002 1017 2021 10.1038/s43018-021-00249-x 34790902
111 Bäumer N Scheller A Wittmann L Faust A Apel M Nimmagadda SC Geyer C Grunert K Kellmann N Peipp M Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia J Hematol Oncol 15 171 2022 10.1186/s13045-022-01390-5 36457063
